# Endo Use Shortacting Octreotide Preconception

> Recommends utilizing short-acting octreotide subcutaneous injections for disease control while awaiting conception after discontinuing long-acting somatostatin receptor ligands or pegvisomant. Trigger phrases include “preconception window,” “discontinuing long-acting SRL,” and “short-acting octreotide as needed until conception.”

- Skill: `dromlakhani/endo-use-shortacting-octreotide-preconception` (Agent Skill)
- Install (CLI): `npx skillmds@latest add dromlakhani/endo-use-shortacting-octreotide-preconception`
- Raw SKILL.md: https://api.skillmd.com/api/skills/dromlakhani/endo-use-shortacting-octreotide-preconception/raw
- Safety review: pending (external: skill-scanner PASS, skillspector PASS)
- Works with: Claude Code, Claude.ai, OpenAI Codex
- Category: Coding & Dev Tools
- Author: dromlakhani (https://skillmd.com/u/dromlakhani)
- Updated: 2026-09-08
- Page: https://skillmd.com/skills/dromlakhani/endo-use-shortacting-octreotide-preconception

---


# Use short-acting octreotide as needed until conception

## STEP 1 — Gather Information
Confirm diagnosis of acromegaly, current long-acting SRL (octreotide LAR or lanreotide autogel) or pegvisomant therapy, and pregnancy intention; assess timing for discontinuation (~2 months before conception attempt), baseline symptoms, tumor size, and IGF-1 levels to determine need for ongoing disease control.

## STEP 2 — Rule In / Rule Out
If the patient has asymptomatic disease with low tumor burden and normal IGF-1, consider holding all therapy; if symptomatic, progressive tumor growth, or elevated IGF-1 indicating need for control, proceed to short-acting octreotide.

## STEP 3 — Classify or Stratify
For patients requiring therapy, prescribe short-acting octreotide 50–100 mcg subcutaneously every 6–8 hours as needed for symptoms or biochemical control, adjusting based on headache, IGF-1 trends, and tumor-related signs.

## STEP 4 — Decide
Continue short-acting octreotide until a positive pregnancy test confirms conception, then discontinue all medical therapy except for tumor- or headache-related indications per pregnancy guidance.

## Clinical Guardrails / Mimics / Pitfalls
Do not use long-acting SRL or pegvisomant during pregnancy due to placental transfer and limited safety data; avoid relying on GH/IGF-1 monitoring in pregnancy as placental GH confounds assays; monitor for hypoglycemia and injection-site reactions; use the lowest effective dose and assess tumor growth clinically (headaches, visual fields) rather than biochemical markers.

## Concrete Clinical Example
A 32-year-old woman on octreotide LAR 30 mg monthly plans pregnancy; she discontinues LAR 2 months before attempting conception, develops mild headaches and elevated IGF-1, starts short-acting octreotide 50 mcg SC TID PRN, continues until pregnancy test positive, then stops therapy and undergoes serial visual field monitoring for tumor growth.

**Source:** Acromegaly: An Endocrine Society Clinical Practice Guideline, Katznelson et al., 2014, doi:10.1210/jc.2014-2700